Prospective Registry of rivaroxaban management of cancer-associated venous thromboembolism study
- Conditions
- Cancer-associated venous Thromboembolism
- Registration Number
- JPRN-UMIN000034933
- Lead Sponsor
- International University of Health and Welfare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 500
Not provided
1.Patients who have passed at least 2 weeks from diagnosis of VTE to the start of anticoagulant therapy. 2.Patients to whom the study drugs are contraindicated (see the package inserts) 3.Patients with active hemorrhage at the time of diagnosis of VTE 4.Other patients who are judged to be inappropriate by the physician in charge Ex. Inability or unwillingness to comply with the study related procedures, or employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator, etc. 5.Patients who are unlikely to receive anticoagulant therapy over three months.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence/aggravation of symptomatic venous thromboembolism All the patients suspected for efficacy or safety events and all the cases of death will be judged by the event evaluation committee based on detailed data to decide the event applicable. The event evaluation committee is authorized to ask the physician in charge for the supply of additional information necessary for the judgment of these events. Each endpoint will be assessed by descriptive statistics, and will not be compared between study drugs.
- Secondary Outcome Measures
Name Time Method